Eagle Pharmaceuticals Statistics
Share Statistics
Eagle Pharmaceuticals has 12.96M shares outstanding. The number of shares has increased by -0.22% in one year.
| Shares Outstanding | 12.96M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.22% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 6.28M |
| Failed to Deliver (FTD) Shares | 34 |
| FTD / Avg. Volume | 0.11% |
Short Selling Information
The latest short interest is 350.53K, so 2.71% of the outstanding shares have been sold short.
| Short Interest | 350.53K |
| Short % of Shares Out | 2.71% |
| Short % of Float | 5.59% |
| Short Ratio (days to cover) | 3.91 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is 0.24.
| PE Ratio | 0 |
| Forward PE | 0.24 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | n/a |
Enterprise Valuation
Eagle Pharmaceuticals Inc. has an Enterprise Value (EV) of 366.93M.
| EV / Earnings | 10.3 |
| EV / Sales | 1.16 |
| EV / EBITDA | 4.73 |
| EV / EBIT | 4.53 |
| EV / FCF | 11.91 |
Financial Position
The company has a current ratio of 0, with a Debt / Equity ratio of 0.
| Current Ratio | 0 |
| Quick Ratio | 0 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0% and return on capital (ROIC) is 15.59%.
| Return on Equity (ROE) | 0% |
| Return on Assets (ROA) | 0% |
| Return on Capital (ROIC) | 15.59% |
| Revenue Per Employee | 2.36M |
| Profits Per Employee | 265.99K |
| Employee Count | 134 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 25.79M |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -84.74% in the last 52 weeks. The beta is 0.62, so Eagle Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.62 |
| 52-Week Price Change | -84.74% |
| 50-Day Moving Average | 0.69 |
| 200-Day Moving Average | 3.22 |
| Relative Strength Index (RSI) | 51.62 |
| Average Volume (20 Days) | 29.71K |
Income Statement
In the last 12 months, Eagle Pharmaceuticals had revenue of 316.61M and earned 35.64M in profits. Earnings per share was 2.76.
| Revenue | 316.61M |
| Gross Profit | 221.67M |
| Operating Income | 80.96M |
| Net Income | 35.64M |
| EBITDA | 77.50M |
| EBIT | 80.96M |
| Earnings Per Share (EPS) | 2.76 |
Balance Sheet
The company has 55.32M in cash and 67.79M in debt, giving a net cash position of -12.47M.
| Cash & Cash Equivalents | 55.32M |
| Total Debt | 67.79M |
| Net Cash | -12.47M |
| Retained Earnings | 111.50M |
| Total Assets | 404.82M |
| Working Capital | 100.62M |
Cash Flow
In the last 12 months, operating cash flow was 30.80M and capital expenditures 0, giving a free cash flow of 30.80M.
| Operating Cash Flow | 30.80M |
| Capital Expenditures | 0 |
| Free Cash Flow | 30.80M |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | 24.48% |
| EBIT Margin | 25.57% |
| FCF Margin | 9.73% |
Dividends & Yields
EGRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 424.62% |
| FCF Yield | 365.64% |
Analyst Forecast
Currently there are no analyst rating for EGRX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 1.68 |
| Piotroski F-Score | 4 |